BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Marchion DC, Bicaku E, Xiong Y, Bou Zgheib N, Al Sawah E, Stickles XB, Judson PL, Lopez AS, Cubitt CL, Gonzalez-Bosquet J, Wenham RM, Apte SM, Berglund A, Lancaster JM. A novel c-Met inhibitor, MK8033, synergizes with carboplatin plus paclitaxel to inhibit ovarian cancer cell growth. Oncol Rep 2013;29:2011-8. [PMID: 23467907 DOI: 10.3892/or.2013.2329] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Gawde KA, Sau S, Tatiparti K, Kashaw SK, Mehrmohammadi M, Azmi AS, Iyer AK. Paclitaxel and di-fluorinated curcumin loaded in albumin nanoparticles for targeted synergistic combination therapy of ovarian and cervical cancers. Colloids and Surfaces B: Biointerfaces 2018;167:8-19. [DOI: 10.1016/j.colsurfb.2018.03.046] [Cited by in Crossref: 45] [Cited by in F6Publishing: 40] [Article Influence: 11.3] [Reference Citation Analysis]
2 Kim JH, Jang HJ, Kim HS, Kim BJ, Park SH. Prognostic impact of high c-Met expression in ovarian cancer: a meta-analysis. J Cancer 2018;9:3427-34. [PMID: 30310499 DOI: 10.7150/jca.26071] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
3 Spina A, De Pasquale V, Cerulo G, Cocchiaro P, Della Morte R, Avallone L, Pavone LM. HGF/c-MET Axis in Tumor Microenvironment and Metastasis Formation. Biomedicines 2015;3:71-88. [PMID: 28536400 DOI: 10.3390/biomedicines3010071] [Cited by in Crossref: 25] [Cited by in F6Publishing: 27] [Article Influence: 3.6] [Reference Citation Analysis]
4 Thibault B, Jean-Claude B. Dasatinib + Gefitinib, a non platinum-based combination with enhanced growth inhibitory, anti-migratory and anti-invasive potency against human ovarian cancer cells. J Ovarian Res 2017;10:31. [PMID: 28446239 DOI: 10.1186/s13048-017-0319-2] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
5 Wood GE, Hockings H, Hilton DM, Kermorgant S. The role of MET in chemotherapy resistance. Oncogene 2021;40:1927-41. [PMID: 33526881 DOI: 10.1038/s41388-020-01577-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
6 Li E, Hu Z, Sun Y, Zhou Q, Yang B, Zhang Z, Cao W. Small molecule inhibitor of c-Met (PHA665752) suppresses the growth of ovarian cancer cells and reverses cisplatin resistance. Tumour Biol 2016;37:7843-52. [PMID: 26695152 DOI: 10.1007/s13277-015-4318-x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.6] [Reference Citation Analysis]
7 Jiang X, Feng K, Zhang Y, Li Z, Zhou F, Dou H, Wang T. Sorafenib and DE605, a novel c-Met inhibitor, synergistically suppress hepatocellular carcinoma. Oncotarget 2015;6:12340-56. [PMID: 25895026 DOI: 10.18632/oncotarget.3656] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 3.5] [Reference Citation Analysis]
8 Van Der Steen N, Pauwels P, Gil-Bazo I, Castañon E, Raez L, Cappuzzo F, Rolfo C. cMET in NSCLC: Can We Cut off the Head of the Hydra? From the Pathway to the Resistance. Cancers (Basel) 2015;7:556-73. [PMID: 25815459 DOI: 10.3390/cancers7020556] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 3.1] [Reference Citation Analysis]
9 Keedy VL, Lenz HJ, Saltz L, Whisenant JG, Berlin JD, Camacho LH. First-in-human phase I dose escalation study of MK-8033 in patients with advanced solid tumors. Invest New Drugs 2018;36:860-8. [PMID: 29376210 DOI: 10.1007/s10637-018-0567-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
10 Stella GM, Gentile A, Balderacchi A, Meloni F, Milan M, Benvenuti S. Ockham's razor for the MET-driven invasive growth linking idiopathic pulmonary fibrosis and cancer. J Transl Med 2016;14:256. [PMID: 27590450 DOI: 10.1186/s12967-016-1008-4] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
11 Mezquita B, Pineda E, Mezquita J, Mezquita P, Pau M, Codony-servat J, Martínez-balibrea E, Mora C, Maurel J, Mezquita C. LoVo colon cancer cells resistant to oxaliplatin overexpress c-MET and VEGFR-1 and respond to VEGF with dephosphorylation of c-MET: CHEMOTHERAPY RESISTANT COLON CANCER CELLS. Mol Carcinog 2016;55:411-9. [DOI: 10.1002/mc.22289] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
12 Koussounadis A, Langdon SP, Um I, Kay C, Francis KE, Harrison DJ, Smith VA. Dynamic modulation of phosphoprotein expression in ovarian cancer xenograft models. BMC Cancer 2016;16:205. [PMID: 26964739 DOI: 10.1186/s12885-016-2212-6] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
13 Lo CM, Lo JC, Sato PY, Yeung TL, Mok SC, Yip KP. Monitoring of ovarian cancer cell invasion in real time with frequency-dependent impedance measurement. Am J Physiol Cell Physiol 2016;311:C1040-7. [PMID: 27784677 DOI: 10.1152/ajpcell.00211.2016] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
14 Moran-Jones K. The Therapeutic Potential of Targeting the HGF/cMET Axis in Ovarian Cancer. Mol Diagn Ther 2016;20:199-212. [PMID: 27139908 DOI: 10.1007/s40291-016-0201-8] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
15 Delitto D, Vertes-George E, Hughes SJ, Behrns KE, Trevino JG. c-Met signaling in the development of tumorigenesis and chemoresistance: Potential applications in pancreatic cancer. World J Gastroenterol 2014; 20(26): 8458-8470 [PMID: 25024602 DOI: 10.3748/wjg.v20.i26.8458] [Cited by in CrossRef: 47] [Cited by in F6Publishing: 44] [Article Influence: 5.9] [Reference Citation Analysis]
16 Geng S, Gu L, Ju F, Zhang H, Wang Y, Tang H, Bi Z, Yang C. MicroRNA-224 promotes the sensitivity of osteosarcoma cells to cisplatin by targeting Rac1. J Cell Mol Med 2016;20:1611-9. [PMID: 27222381 DOI: 10.1111/jcmm.12852] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 4.7] [Reference Citation Analysis]
17 Kim HJ, Yoon A, Ryu JY, Cho YJ, Choi JJ, Song SY, Bang H, Lee JS, Cho WC, Choi CH, Lee JW, Kim BG, Bae DS. c-MET as a Potential Therapeutic Target in Ovarian Clear Cell Carcinoma. Sci Rep 2016;6:38502. [PMID: 27917934 DOI: 10.1038/srep38502] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 3.3] [Reference Citation Analysis]
18 Moran-Jones K, Brown LM, Samimi G. INC280, an orally available small molecule inhibitor of c-MET, reduces migration and adhesion in ovarian cancer cell models. Sci Rep 2015;5:11749. [PMID: 26138303 DOI: 10.1038/srep11749] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 2.4] [Reference Citation Analysis]
19 Zhang Z, Huang K, Gu C, Zhao L, Wang N, Wang X, Zhao D, Zhang C, Lu Y, Meng Y. Molecular Subtyping of Serous Ovarian Cancer Based on Multi-omics Data. Sci Rep 2016;6:26001. [PMID: 27184229 DOI: 10.1038/srep26001] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 3.7] [Reference Citation Analysis]